Inhibition of myeloperoxidase enhances immune checkpoint therapy for melanoma
Abstract
The presence of a highly immunosuppressive tumor microenvironment has limited the success of immune checkpoint therapy (ICT). Immune suppressing myeloid cells with increased production of reactive oxygen species are critical drivers of this immunosuppressive tumor microenvironment. Strategies to limit these immune suppressing myeloid cells are needed to enhance response to ICT.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 01, 2023
- Source ID
- 10.1136/jitc-2022-005837
Entities
People
- David Piwnica-Worms
- Jing Wang
- Ping Yang
- Seth Gammon
- Tracy Liu
- Wencai Ma
Organizations
- National Cancer Institute
- National Institute of General Medical Sciences
- United States Department of Defense